Post by account_disabled on Feb 17, 2024 3:22:43 GMT -5
Prostate cancer is considered the second most common malignant disease in men and the fifth cause of cancer death worldwide. In 2021 alone, around 35,764 new cases of prostate cancer were registered, a figure that continues to increase progressively. However, some recent statistics reflect that 75% of all tumors of this pathology that are located early are curable. By taboolayou may like 9 easy desserts to make at home with these quick and simple recipes in this context, mirnax biosens , in collaboration with the puerta de hierro hospital, has launched a clinical trial to evaluate a novel method for diagnosing prostate cancer. This approach, based on micro-rnas (mirs) , small molecules in the body, promises more effective detection of prostate cancer.
An innovative method for detecting prostate cancer the testing method uses a small sample, similar to the regular prostate specific antigen (psa) test, a conventional test that identifies prostate cancer through a simple blood sample. Furthermore, this new test is integrated into the mirnax biosens healthcore system, which also has the molecular diagnosis methods for colon cancer and cardiac pathologies validated by the british health Europe Cell Phone Number List system. This test provides more accurate confirmation of the presence of prostate cancer compared to currently available tests. This innovative approach could represent a significant advance in the diagnosis and monitoring of this disease. After the successful conclusion of the initial phase of the clinical trial, led by the working group formed by the urology service of the puerta de hierro- majadahonda university hospital represented by its head of service prof.
Joaquín carballido) and mirnax biosens, advances to the next stage. This phase will determine the practical viability of the method for clinical implementation and its usefulness in the diagnosis and monitoring of prostate cancer. Using technology to combat prostate cancer this diagnostic method, faster and less invasive for patients, could offer an effective and precise alternative in the fight against prostate cancer. The combination of medical expertise and technological innovation opens new possibilities to improve the detection and management of this disease. In this context, the incorporation of this resource to the urology service represents the possibility of revolutionizing the process of care for patients who require active monitoring of prostate cancer.